Download the free whitepaper: Unravelling the complexities of genomics-driven drug discovery

Genomics-driven drug discovery holds immense promise in developing targeted therapies by leveraging genetic and biomarker information to understand the root causes of diseases. However, the field faces significant hurdles.

In this whitepaper, we examine the obstacles of limited recontactability, scarcity of multi-omics data sets, lack of diversity in data, and the challenge of scaling research for rare diseases. By addressing these challenges and proposing strategies to address them, this whitepaper aims to chart a path by which we can harness the full potential of genomics-driven drug discovery.

 

whitepaper image
download icon

Download whitepaper

AAV gene therapy trends: Navigating the boom in viral vectors

Adeno-associated virus (AAV) has rapidly become the leading vector for in vivo gene therapies, powering nearly a third of global approvals to date. In 2025, momentum continues with new regulatory designations in ophthalmology, neurology, and systemic diseases—yet safety concerns, manufacturing bottlenecks, and commercial headwinds highlight the need for more disciplined development.

In this whitepaper, we explore the promise and pressures shaping the future of AAV gene therapy, from capsid engineering and trial design innovations to strategies that make recruitment, retention, and delivery more efficient.

Download now to learn more.

AAVgroup